Steff Ann-Muriel, Monroe James, Friedrich Kristian, Chandramouli Sumana, Nguyen Thi Lien-Anh, Tian Sai, Vandepaer Sarah, Toussaint Jean-François, Carfi Andrea
GSK Vaccines, 14200 Shady Grove Road, Rockville, MD, 20850, USA.
Takeda Vaccines, 75 Sidney Street, Cambridge, MA, 02139, USA.
Nat Commun. 2017 Oct 20;8(1):1085. doi: 10.1038/s41467-017-01092-4.
Human respiratory syncytial virus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older adults, and remains an important vaccine need. RSV fusion (F) glycoprotein is a key target for neutralizing antibodies. RSV F stabilized in its pre-fusion conformation (DS-Cav1 F) induces high neutralizing antibody titers in naïve animals, but it remains unknown to what extent pre-fusion F can boost pre-existing neutralizing responses in RSV seropositive adults. We here assess DS-Cav1 F immunogenicity in seropositive cattle pre-exposed to bovine RSV, a virus closely related to hRSV. A single immunization with non-adjuvanted DS-Cav1 F strongly boosts RSV neutralizing responses, directed towards pre-fusion F-specific epitopes, whereas a post-fusion F is unable to do so. Vaccination with pre-fusion F thus represents a promising strategy for maternal immunization and for other RSV vaccine target populations such as older adults.
人呼吸道合胞病毒(hRSV)可导致婴儿和老年人患上严重的下呼吸道疾病,仍然是一种急需疫苗预防的病毒。RSV融合(F)糖蛋白是中和抗体的关键靶点。稳定在其融合前构象的RSV F(DS-Cav1 F)可在未接触过该病毒的动物中诱导出高中和抗体滴度,但融合前F在多大程度上能增强RSV血清阳性成年人中已有的中和反应仍不清楚。我们在此评估DS-Cav1 F在预先接触过牛RSV(一种与hRSV密切相关的病毒)的血清阳性牛中的免疫原性。用无佐剂的DS-Cav1 F进行单次免疫可强烈增强针对融合前F特异性表位的RSV中和反应,而后融合F则无法做到这一点。因此,用融合前F进行疫苗接种是一种用于母体免疫以及其他RSV疫苗目标人群(如老年人)的有前景的策略。